Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder

Trial Profile

Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2016

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Bipolar disorders; Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 11 Aug 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 11 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top